拉替拉韦与依非韦伦初始抗逆转录病毒治疗的4年艾滋病或死亡风险比较
本研究利用美国观察性队列数据,比较415例起始拉替拉韦方案与2646例起始依非韦伦方案(均含恩曲他滨和替诺福韦DF)患者的4年艾滋病或死亡风险。结论认为两方案4年临床效果相近,需持续观察长期比较效果。
要点
- 拉替拉韦与依非韦伦初始方案的4年艾滋病或死亡风险无显著差异。
- 研究基于观察性数据,需警惕长期比较效果的不确定性。
核心结论
- 拉替拉韦与依非韦伦为基础的初始抗逆转录病毒治疗具有相似的4年临床效果。
研究设计与样本
- 观察性队列研究,利用美国Centers for AIDS Research Network of Integrated Clinical Systems和Centers for Disease Control and Prevention的数据。
- 纳入415例起始拉替拉韦方案和2646例起始依非韦伦方案(均含恩曲他滨和替诺福韦DF)的成人患者。
- 采用标准化方法处理混杂、选择偏倚和泛化性,报告意向治疗和符合方案两种估计。
主要发现
- 治疗起始时,12%为女性,36%为黑人,13%为西班牙裔;中位年龄37岁,CD4计数321 cells/µL,病毒载量4.5 log10 copies/mL。
临床怎么用
- 在初始抗逆转录病毒治疗选择中,拉替拉韦和依非韦伦方案可视为具有相似的4年临床效果。
- 鉴于观察性数据的局限性,需对HIV方案的长期比较效果保持警惕。
局限性
- 研究为观察性设计,可能存在未测量混杂。
- 大规模实验数据尚不可得,需依赖观察性数据持续评估长期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND.: The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown. METHODS.: We use observational data from the Centers for AIDS Research Network of Integrated Clinical Systems and the Centers for Disease Control and Prevention to estimate 4-year risk of AIDS and all-cause mortality among 415 patients starting a raltegravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine and tenofovir disoproxil fumarate). We account for confounding and selection bias as well as generalizability by standardization for measured variables, and present both observational intent-to-treat and per-protocol estimates. RESULTS.: At treatment initiation, 12% of patients were female, 36% black, 13% Hispanic; median age was 37 years, CD4 count 321 cells/µL, and viral load 4.5 log10 copies/mL. Two hundred thirty-five patients incurred an AIDS-defining illness or died, and 741 patients left follow-up. After accounting for measured differences, the 4-year risk was similar among those starting both regimens (ie, intent-to treat hazard ratio [HR], 0.96 [95% confidence interval {CI}, .63-1.45]; risk difference, -0.9 [95% CI, -4.5 to 2.7]), as well as among those remaining on regimens (ie, per-protocol HR, 0.95 [95% CI, .59-1.54]; risk difference, -0.5 [95% CI, -3.8 to 2.9]). CONCLUSIONS.: Raltegravir and efavirenz-based initial antiretroviral therapy have similar 4-year clinical effects. Vigilance regarding longer-term comparative effectiveness of HIV regimens using observational data is needed because large-scale experimental data are not forthcoming.
引用
- Cole SR, Edwards JK, Hall HI, et al. Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States. Clin Infect Dis. 2017. PMID: 28498892. doi:10.1093/cid/cix199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。